Clinical Trials

Randomized, Non-comparative Neoadjuvant Phase II Study in Patients with ER+/HER2- Breast Cancer 2 cm with Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole


Study ID
CA209-7A8

NCT Number
NCT04075604 (Click on the NCT number for more information about the trial)

Principle Investigator
Dr. Waintraub, Stanley

Phase
II

Sponsor
Bristol-Myers Squibb


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now